Experimental drug ‘shows promise’ for treating primary biliary cholangitis
More patients treated with seladelpar had a biochemical response and reduction in pruritus versus placebo.
For patients with primary biliary cholangitis, those given seladelpar — a peroxisome proliferator-activated receptor (PPAR) delta agonist — are more likely to have a biochemical response and ALP normalisation compared to placebo, according to a study in The New England Journal of Medicine.
Researchers from the University Health Network in Toronto, Canada, conducted a year-long phase 3, trial involving 193 patients with primary biliary cholangitis with inadequate response to, or who had a history of unacceptable side effects with, ursodeoxycholic acid.
